In	IN	O
patients	NNS	WHO
with	IN	WHO
chronic	JJ	WHO
kidney	NN	WHO
disease	NN	WHO
and	CC	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
less	JJR	O
than	IN	O
60	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
VYTORIN	NNP	O
is	VBZ	O
10	CD	DOS
/	JJ	O
20	CD	DOS
/	JJ	O
18	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
AmBisome	NNP	O
for	IN	O
each	DT	O
indication	NN	O
for	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
folic	JJ	O
acid	NNS	O
studied	VBD	O
ranged	VBN	O
from	IN	O
350	CD	DOS
to	TO	O
1000	CD	DOS
mcg	NN	UNIT
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
vitamin	NN	O
B12	NNP	O
was	VBD	O
1000	CD	DOS
mcg	NN	UNIT
.	.	O

Each	DT	O
vial	NN	O
of	IN	O
ALDURAZYME	NNP	O
provides	VBZ	O
2.9	CD	DOS
milligrams	NNS	UNIT
(	(	O
mg	NN	UNIT
)	)	O
of	IN	O
laronidase	NN	O
in	IN	O
5	CD	DOS
milliliters	NNS	UNIT
(	(	O
mL	NN	O
)	)	O
of	IN	O
solution	NN	O
and	CC	O
is	VBZ	O
intended	VBN	O
for	IN	O
single	JJ	O
use	NN	O
only	RB	O
.	.	O

Alosetron	NNP	O
hydrochloride	NN	O
tablets	NNS	O
is	VBZ	O
extensively	RB	O
metabolized	VBN	O
by	IN	O
the	DT	O
liver	NN	O
,	,	O
and	CC	O
increased	VBD	O
exposure	NN	O
to	TO	O
alosetron	VB	O
hydrochloride	JJ	O
tablets	NNS	O
is	VBZ	O
likely	JJ	O
to	TO	O
occur	VB	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTIMMUNE	NNP	O
administered	VBD	O
subcutaneously	RB	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
CGD	NNP	WHO
and	CC	WHO
SMO	NNP	WHO
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
below	IN	O
:	:	O

0	CD	DOS
-	:	O
0.03PPM	CD	DOS

For	IN	O
adults	NNS	WHO
,	,	O
an	DT	O
initial	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NN	UNIT
of	IN	O
ALDACTONE	NNP	O
administered	VBD	O
in	IN	O
either	DT	O
single	JJ	DOS
or	CC	O
divided	JJ	UNIT
doses	NNS	UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	WHO
patients	NNS	WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
salmeterol	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
taking	VBG	WHO
danazol	NN	WHO
,	,	O
diltiazem	NN	O
,	,	O
or	CC	O
verapamil	NNS	O
concomitantly	RB	WHO
with	IN	O
lovastatin	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
)	)	O
,	,	O
therapy	NN	O
should	MD	O
begin	VB	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
of	IN	O
lovastatin	NN	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
patient	NN	O
should	MD	O
place	VB	O
the	DT	O
ACTIQ	NNP	O
unit	NN	O
in	IN	O
his	PRP$	O
or	CC	O
her	PRP$	O
mouth	NN	O
between	IN	O
the	DT	O
cheek	NN	O
and	CC	O
lower	JJR	O
gum	NN	O
,	,	O
occasionally	RB	O
moving	VBG	O
the	DT	O
drug	NN	O
matrix	NN	O
from	IN	O
one	CD	O
side	NN	O
to	TO	O
the	DT	O
other	JJ	O
using	VBG	O
the	DT	O
handle	NN	O
.	.	O

Take	VB	O
a	DT	O
multivitamin	NN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
at	IN	O
bedtime	NN	O
,	,	O
when	WRB	O
using	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
capsules	NNS	O
.	.	O

A	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
no	DT	O
greater	JJR	O
than	IN	O
6	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

1	CD	DOS
mg	NN	UNIT

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
of	IN	O
this	DT	O
preparation	NN	O
varies	VBZ	O
from	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mL	NNS	UNIT
at	IN	O
intervals	NNS	O
of	IN	O
1	CD	O
to	TO	O
3	CD	O
days	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AROMASIN	NNP	O
in	IN	O
early	JJ	O
and	CC	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
is	VBZ	O
one	CD	DOS
25	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
once	IN	FREQ
daily	JJ	FREQ
after	IN	O
a	DT	O
meal	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
more	RBR	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
loop	NN	O
diuretics	NNS	O
are	VBP	O
preferred	VBN	O
to	TO	O
thiazides	NNS	O
.	.	O

Give	VB	O
first	JJ	O
dose	NN	O
on	IN	O
awakening	VBG	O
;	:	O
additional	JJ	O
doses	NNS	O
(	(	O
1	CD	DOS
or	CC	O
2	CD	DOS
)	)	O
at	IN	O
intervals	NNS	O
of	IN	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
.	.	O

The	DT	O
total	JJ	O
dose	NN	O
of	IN	O
Acetadote	NNP	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
3	CD	DOS
separate	JJ	UNIT
doses	NNS	UNIT
and	CC	O
administered	VBN	O
over	IN	O
a	DT	O
total	NN	O
of	IN	O
21	CD	O
hours	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
after	IN	O
4	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
higher	JJR	O
doses	NNS	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

During	IN	O
dialysis	NN	O
,	,	O
perindopril	NN	O
is	VBZ	O
removed	VBN	O
with	IN	O
the	DT	O
same	JJ	O
clearance	NN	O
as	IN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
normal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
1	CD	DOS
mg	NN	UNIT
.	.	O

Concomitant	JJ	O
Therapy	NN	O
:	:	O
If	IN	O
AGENERASE	NNP	O
and	CC	O
ritonavir	NN	O
are	VBP	O
used	VBN	O
in	IN	O
combination	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
regimens	NNS	O
are	VBP	O
:	:	O
AGENERASE	$	O
1,200	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
200	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
AGENERASE	$	O
600	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
100	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Amphadase®	NNP	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
small	JJ	O
volumes	NNS	O
of	IN	O
solution	NN	O
(	(	O
up	IN	O
to	TO	O
200	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
such	JJ	O
as	IN	O
small	JJ	O
clysis	NN	O
for	IN	O
infants	NNS	WHO
or	CC	O
solutions	NNS	O
of	IN	O
drugs	NNS	O
for	IN	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

The	DT	O
usual	JJ	O
effective	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
-	:	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
but	CC	O
higher	JJR	O
doses	NNS	O
may	MD	O
be	VB	O
required	VBN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
.	.	O

Most	JJS	WHO
patients	NNS	WHO
have	VBP	O
required	VBN	O
dosages	NNS	O
of	IN	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
80	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
body	NN	WHO
weight	NN	WHO
greater	JJR	WHO
than	IN	WHO
20	CD	WHO
kg	NNS	WHO
should	MD	O
receive	VB	O
a	DT	O
total	JJ	O
volume	NN	O
of	IN	O
250	CD	DOS
mL	NN	UNIT
.	.	O

The	DT	O
usual	JJ	O
IV	NNP	O
dose	NN	O
is	VBZ	O
16	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
.	.	O

Titrate	NNP	O
GRALISE	NNP	O
to	TO	O
an	DT	O
1800	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

Infants	NNS	WHO
should	MD	O
receive	VB	O
a	DT	O
1	CD	O
to	TO	O
2	CD	O
hour	NN	O
infusion	NN	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Body	NNP	WHO
Weight	NNP	WHO
≥	VBZ	WHO
50	CD	WHO
kg	NN	WHO
:	:	O
Administer	NNP	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

Increase	NNP	O
to	TO	O
40	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
based	VBN	O
upon	IN	O
individual	JJ	O
tolerability	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ABRAXANE	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
on	IN	O
Days	NNP	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

Telephone	CD	O
1	CD	O
-	:	O
866­792	CD	O
-	:	O
5172	CD	O
.	.	O

Recommended	VBN	O
starting	JJ	O
dosage	NN	O
of	IN	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

A	DT	O
patient	NN	WHO
who	WP	WHO
becomes	VBZ	WHO
hypotensive	VBP	WHO
at	IN	WHO
this	DT	WHO
dose	NN	WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
1.25	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
and	CC	O
after	IN	O
one	CD	PER
week	NN	PER
at	IN	O
the	DT	O
starting	VBG	O
dose	NN	O
,	,	O
patients	NNS	O
should	MD	O
then	RB	O
be	VB	O
titrated	VBN	O
(	(	O
if	IN	O
tolerated	VBN	O
)	)	O
toward	IN	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
with	IN	O
dosage	NN	O
increases	NNS	O
being	VBG	O
about	IN	O
3	CD	PER
weeks	NNS	PER
apart	RB	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	WHO
patients	NNS	WHO
with	IN	WHO
cardiovascular	JJ	WHO
disease	NN	WHO
the	DT	O
drug	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
to	TO	O
a	DT	O
final	JJ	O
infusion	NN	O
concentration	NN	O
of	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

Intraspinal	JJ	O
use	NN	O
(	(	O
Amp	NNP	O
88	CD	O
)	)	O
-	:	O
Usual	JJ	O
dose	NN	O
is	VBZ	O
0.2	CD	DOS
to	TO	O
0.4	CD	DOS
mL	NN	UNIT
(	(	O
0.2	CD	DOS
to	TO	O
0.4	CD	DOS
mg	NN	UNIT
)	)	O
added	VBD	O
to	TO	O
anesthetic	JJ	O
spinal	JJ	O
fluid	NN	O
mixture	NN	O
(	(	O
may	MD	O
prolong	VB	O
anesthetic	JJ	O
action	NN	O
by	IN	O
limiting	VBG	O
absorption	NN	O
)	)	O
.	.	O

The	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

To	TO	O
combine	VB	O
two	CD	DOS
or	CC	O
more	JJR	O
vials	NNS	O
of	IN	O
ALPROLIX™	NNP	O
,	,	O
follow	VBP	O
the	DT	O
following	VBG	O
pooling	JJ	O
steps	NNS	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Dovonex®	NNP	O
(	(	O
calcipotriene	JJ	O
ointment	NN	O
)	)	O
ointment	NN	O
once	RB	FREQ
or	CC	O
twice	JJ	FREQ
daily	JJ	FREQ
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
and	CC	O
completely	RB	O
.	.	O

Repeat	JJ	O
administration	NN	O
:	:	O
If	IN	O
conversion	NN	O
of	IN	O
PSVT	NNP	O
does	VBZ	O
not	RB	O
occur	VB	O
within	IN	O
1	CD	O
-	:	O
2	CD	O
minutes	NNS	O
,	,	O
additional	JJ	O
bolus	NN	O
injections	NNS	O
of	IN	O
adenosine	NN	O
can	MD	O
be	VB	O
administered	VBN	O
at	IN	O
incrementally	RB	O
higher	JJR	O
doses	NNS	O
,	,	O
increasing	VBG	O
the	DT	O
amount	NN	O
given	VBN	O
by	IN	O
0.05	CD	DOS
to	TO	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

Preparation	NN	O
and	CC	O
Storage	NN	O
of	IN	O
Parenteral	JJ	O
Solution	NN	O
:	:	O
Each	DT	O
500	CD	DOS
mg	NN	UNIT
vial	JJ	UNIT
containing	VBG	O
sterile	JJ	O
acetazolamide	JJ	O
sodium	NN	O
should	MD	O
be	VB	O
reconstituted	VBN	O
with	IN	O
at	IN	O
least	JJS	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

The	DT	O
patient	NN	O
may	MD	O
be	VB	O
kept	VBN	O
on	IN	O
his	PRP$	O
schedule	NN	O
until	IN	O
again	RB	O
95	CD	O
percent	NN	O
clear	JJ	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
univasc®	JJ	O
in	IN	O
patients	NNS	WHO
not	RB	WHO
receiving	VBG	WHO
diuretics	NNS	WHO
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
,	,	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
meals	NNS	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
objective	NN	O
of	IN	O
nutritional	JJ	O
management	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
liver	JJ	WHO
disease	NN	WHO
is	VBZ	O
the	DT	O
provision	NN	O
of	IN	O
sufficient	JJ	O
amino	NN	O
acid	NN	O
and	CC	O
caloric	JJ	O
support	NN	O
for	IN	O
protein	NN	O
synthesis	NN	O
without	IN	O
exacerbating	VBG	O
hepatic	JJ	O
encephalopathy	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
lesser	JJR	WHO
degrees	NNS	WHO
of	IN	WHO
impairment	NN	WHO
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
and	CC	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
8	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Pediatric	NNP	WHO
<	NN	WHO
Patients	NNS	WHO
:	:	O
For	IN	O
children	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
6	CD	WHO
-	:	WHO
15	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
two	CD	DOS
inhalations	NNS	UNIT
may	MD	O
be	VB	O
administered	VBN	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
1	CD	DOS
mg.	NN	UNIT
Higher	JJR	O
doses	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Three	CD	O
Bag	NNP	O
Method	NNP	O
Dosage	NNP	O
Guide	NNP	O
by	IN	O
Weight	NNP	O
in	IN	O
Patients	NNP	WHO
41	CD	WHO
kg	NN	WHO
to	TO	WHO
100	CD	WHO
kg	NNS	WHO

Adults	NNS	WHO
:	:	O
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

A	DT	O
small	JJ	O
quantity	NN	O
of	IN	O
the	DT	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
as	IN	O
required	VBN	O
.	.	O

150	CD	DOS
U	NNP	UNIT
will	MD	O
facilitate	VB	O
absorption	NN	O
of	IN	O
1000	CD	DOS
mL	NN	UNIT
or	CC	O
more	JJR	O
of	IN	O
solution	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
30	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
should	MD	O
receive	VB	O
25	CD	DOS
mg	NN	UNIT
of	IN	O
the	DT	O
solution	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Butalbital	NNP	O
and	CC	O
Acetaminophen	NNP	O
,	,	O
50	CD	DOS
mg	NN	UNIT
/	VBD	O
325	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
:	:	O
One	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
.	.	O

Usual	JJ	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
200	CD	DOS
to	TO	O
300	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Unopened	VBN	O
vials	NNS	O
of	IN	O
lyophilized	VBN	O
material	NN	O
are	VBP	O
to	TO	O
be	VB	O
stored	VBN	O
at	IN	O
temperatures	NNS	O
up	RB	O
to	TO	O
25°	CD	O
C	NNP	O
(	(	O
77°	CD	O
F	NNP	O
)	)	O
.	.	O

A	DT	O
single	JJ	DOS
dose	NN	UNIT
is	VBZ	O
0.5	CD	DOS
mL	NN	UNIT
.	.	O

One	CD	DOS
drop	NN	UNIT
of	IN	O
Isopto®	NNP	O
Carpine	NNP	O
1	CD	O
%	NN	O
,	,	O
2	CD	O
%	NN	O
or	CC	O
4	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
in	IN	O
the	DT	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
up	IN	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
usual	JJ	O
single	JJ	O
dose	NN	O
is	VBZ	O
two	CD	DOS
to	TO	O
three	CD	DOS
inhalations	NNS	UNIT
.	.	O

After	IN	O
at	IN	O
least	JJS	O
one	CD	PER
week	NN	PER
following	VBG	O
the	DT	O
initiation	NN	O
of	IN	O
ritonavir	NN	O
,	,	O
resume	VB	O
ADCIRCA	NNP	O
at	IN	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Onset	NNP	O
of	IN	O
significant	JJ	O
relief	NN	O
of	IN	O
nasal	NN	O
symptoms	NNS	O
was	VBD	O
seen	VBN	O
within	IN	O
two	CD	O
days	NNS	O
after	IN	O
starting	VBG	O
treatment	NN	O
at	IN	O
400	CD	DOS
mcg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
maximum	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
MINTEZOL	NNP	O
(	(	O
thiabendazole	NN	O
)	)	O
is	VBZ	O
3	CD	DOS
grams	NNS	UNIT
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
it	PRP	O
may	MD	O
be	VB	O
possible	JJ	O
to	TO	O
maintain	VB	O
adequate	JJ	O
remission	NN	O
of	IN	O
lesions	NNS	O
with	IN	O
alternate	JJ	O
day	NN	O
or	CC	O
intermittent	JJ	O
therapy	NN	O
.	.	O

Recommended	VBN	O
dose	JJ	O
modifications	NNS	O
for	IN	O
other	JJ	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
adenocarcinoma	NN	WHO
of	IN	O
the	DT	O
pancreas	NNS	O
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
5	CD	O
.	.	O

Refer	NN	O
to	TO	O
Table	VB	O
1	CD	O
for	IN	O
equivalent	JJ	O
doses	NNS	O
of	IN	O
ADZENYS	NNP	O
XR	NNP	O
-	:	O
ODT	NN	O
and	CC	O
ADDERALL	NNP	O
XR	NNP	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
AMPYRA	NNP	O
is	VBZ	O
one	CD	DOS
10	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
,	,	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
,	,	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Attempts	NNS	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
maintain	VB	O
a	DT	O
caloric	JJ	O
intake	NN	O
of	IN	O
greater	JJR	O
than	IN	O
80	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
ALTABAX	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
up	IN	O
to	TO	O
100	CD	O
cm²	NN	O
in	IN	O
total	JJ	O
area	NN	O
in	IN	O
adults	NNS	WHO
or	CC	O
2	CD	O
%	NN	O
total	JJ	O
body	NN	O
surface	NN	O
area	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
aged	VBD	WHO
9	CD	WHO
months	NNS	WHO
or	CC	WHO
older	JJR	WHO
)	)	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
5	CD	PER
days	NNS	PER
.	.	O

SYLVANT	NNP	O
11	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
is	VBZ	O
given	VBN	O
over	IN	O
1	CD	O
hour	NN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
administered	VBD	O
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
until	IN	O
treatment	NN	O
failure	NN	O
.	.	O

Two	CD	PER
weeks	NNS	PER
later	RB	O
(	(	O
Day	NNP	O
29	CD	O
)	)	O
continue	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
other	JJ	FREQ
week	NN	FREQ
.	.	O

ALOXI	NNP	O
is	VBZ	O
supplied	VBN	O
ready	JJ	O
for	IN	O
intravenous	JJ	O
administration	NN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
0.05	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
(	(	O
50	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

When	WRB	O
undiluted	JJ	O
albumin	NN	O
solution	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
normal	JJ	WHO
blood	NN	WHO
volume	NN	WHO
,	,	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
should	MD	O
be	VB	O
slow	JJ	O
enough	RB	O
(	(	O
1	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
)	)	O
to	TO	O
prevent	VB	O
too	RB	O
rapid	JJ	O
expansion	NN	O
of	IN	O
plasma	NN	O
volume	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
VPRIV	NNP	O
dosage	NN	O
in	IN	O
naïve	JJ	WHO
adults	NNS	WHO
and	CC	WHO
naïve	JJ	WHO
pediatric	JJ	WHO
patients	NNS	WHO
4	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
60	CD	DOS
Units	NNS	UNIT
/	VBP	O
kg	NN	O
administered	VBN	O
every	DT	FREQ
other	JJ	FREQ
week	NN	FREQ
as	IN	O
a	DT	O
60	CD	DOS
-	:	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALIMTA	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
10	CD	O
minutes	NNS	O
on	IN	O
Day	NNP	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
cisplatin	NN	O
is	VBZ	O
75	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
infused	VBD	O
over	IN	O
2	CD	O
hours	NNS	O
beginning	VBG	O
approximately	RB	O
30	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
end	NN	O
of	IN	O
ALIMTA	NNP	O
administration	NN	O
.	.	O

This	DT	O
form	NN	O
of	IN	O
administration	NN	O
requires	VBZ	O
very	RB	O
large	JJ	O
volumes	NNS	O
of	IN	O
the	DT	O
solution	NN	O
,	,	O
occasionally	RB	O
as	RB	O
much	JJ	O
as	IN	O
300	CD	DOS
mL	NN	UNIT
during	IN	O
a	DT	O
single	JJ	O
treatment	NN	O
period	NN	O
.	.	O

Calculate	VB	O
the	DT	O
exact	JJ	O
total	JJ	O
dosing	NN	O
volume	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	JJ	O
suspension	NN	O
required	VBN	O
for	IN	O
the	DT	O
patient	NN	O
and	CC	O
slowly	RB	O
withdraw	VB	O
the	DT	O
dosing	NN	O
volume	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
suspension	NN	O
from	IN	O
the	DT	O
vial	NN	O
(	(	O
s	NN	O
)	)	O
into	IN	O
a	DT	O
syringe	NN	O
:	:	O
Dosing	NN	O
volume	NN	O
(	(	O
mL	NN	O
)	)	O
=Total	NN	O
dose	NN	O
(	(	O
mg	NN	UNIT
)	)	O
/	VBZ	O
5	CD	DOS
(	(	O
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Adding	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
TPN	NNP	O
Electrolytes	NNP	O
(	(	O
List	NNP	O
5779	CD	O
)	)	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
chamber	NN	O
and	CC	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Potassium	NNP	O
Phosphate	NNP	O
(	(	O
List	NNP	O
7296	CD	O
)	)	O
to	TO	O
the	DT	O
dextrose	JJ	O
chamber	NN	O
will	MD	O
result	VB	O
in	IN	O
final	JJ	O
admixture	NN	O
concentrations	NNS	O
(	(	O
in	IN	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
as	IN	O
follows	VBZ	O
:	:	O
53	CD	O
sodium	NN	O
,	,	O
42	CD	O
potassium	NN	O
,	,	O
35	CD	O
chloride	NN	O
,	,	O
5	CD	O
magnesium	NN	O
,	,	O
4.5	CD	O
calcium	NN	O
,	,	O
54.7	CD	O
acetate	NN	O
,	,	O
and	CC	O
15	CD	O
(	(	O
mM	NN	O
)	)	O
phosphate	NN	O
.	.	O

Plasma	NNP	O
levels	NNS	O
of	IN	O
ADA	NNP	O
more	JJR	O
than	IN	O
twice	RB	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
35	CD	DOS
μmol	JJ	UNIT
/	NNP	O
hr	NN	O
/	NNP	O
mL	NN	O
have	VBP	O
occurred	VBN	O
on	IN	O
occasion	NN	O
in	IN	O
several	JJ	O
patients	NNS	O
,	,	O
and	CC	O
have	VBP	O
been	VBN	O
maintained	VBN	O
for	IN	O
several	JJ	PER
weeks	NNS	PER
in	IN	O
one	CD	WHO
patient	NN	WHO
who	WP	WHO
received	VBD	WHO
twice	RB	FREQ
weekly	JJ	FREQ
injections	NNS	O
(	(	O
20	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	FW	O
per	IN	O
dose	NN	O
)	)	O
of	IN	O
ADAGEN®	NNP	O
(	(	O
pegademase	VB	O
bovine	NN	O
)	)	O
Injection	NN	O
.	.	O

If	IN	O
ongoing	JJ	O
ABILIFY	NNP	O
therapy	NN	O
is	VBZ	O
clinically	RB	O
indicated	VBN	O
,	,	O
oral	JJ	O
ABILIFY	NNP	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
10	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
should	MD	O
replace	VB	O
ABILIFY	NNP	O
injection	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
[	NN	O
see	VBP	O
Schizophrenia	NNP	O
and	CC	O
Bipolar	NNP	O
I	PRP	O
Disorder	VBP	O
sections	NNS	O
above	IN	O
]	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
by	IN	O
IV	NNP	O
infusion	NN	O
over	IN	O
2	CD	O
hours	NNS	O
.	.	O

Postmarketing	VBG	O
experience	NN	O
suggests	VBZ	O
that	IN	O
elderly	JJ	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
at	IN	O
greater	JJR	O
risk	NN	O
for	IN	O
complications	NNS	O
of	IN	O
constipation	NN	O
;	:	O
therefore	RB	O
,	,	O
appropriate	JJ	O
caution	NN	O
and	CC	O
follow	VB	O
-	:	O
up	RP	O
should	MD	O
be	VB	O
exercised	VBN	O
if	IN	O
alosetron	JJ	O
hydrochloride	NN	O
tablets	NNS	O
are	VBP	O
prescribed	VBN	O
for	IN	O
these	DT	WHO
patients	NNS	WHO
[	VBP	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
to	TO	WHO
AIRDUO	NNP	WHO
RESPICLICK	NNP	WHO
55	CD	DOS
/	VBD	O
14	CD	DOS
mcg	NN	UNIT
after	IN	O
2	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
increasing	VBG	O
the	DT	O
dose	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

The	DT	O
solution	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
adults	NNS	WHO
over	IN	O
a	DT	O
30	CD	O
to	TO	O
60	CD	O
minute	JJ	O
period	NN	O
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
MICRONASE	NNP	O
Tablets	NNP	O
is	VBZ	O
2.5	CD	DOS
to	TO	O
5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
.	.	O

The	DT	O
highest	JJS	O
recommended	VBD	O
dose	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
232	CD	DOS
/	JJ	O
14	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

UVA	NNP	O
exposure	NN	O
may	MD	O
be	VB	O
held	VBN	O
constant	JJ	O
or	CC	O
increased	VBN	O
by	IN	O
up	IN	O
to	TO	O
1.0	CD	DOS
Joule	NNP	UNIT
/	NNP	O
cm²	NN	O
at	IN	O
each	DT	O
treatment	NN	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

d.	NN	O
For	IN	O
patients	NNS	WHO
converting	VBG	WHO
from	IN	WHO
Actiq	NNP	WHO
doses	NNS	WHO
of	IN	O
1200	CD	DOS
and	CC	O
1600	CD	DOS
mcg	NN	UNIT
,	,	O
initiate	JJ	O
titration	NN	O
with	IN	O
200	CD	DOS
mcg	NNS	UNIT
and	CC	O
400	CD	DOS
mcg	JJ	UNIT
Abstral	NNP	O
,	,	O
respectively	RB	O
and	CC	O
proceed	VB	O
using	VBG	O
multiples	NNS	O
of	IN	O
this	DT	O
strength	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
to	TO	O
the	DT	O
starting	NN	O
dosage	NN	O
after	IN	O
2	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
improvement	NN	O
in	IN	O
asthma	NN	O
control	NN	O
.	.	O

These	DT	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
treated	VBN	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
,	,	O
as	IN	O
a	DT	O
Type	NN	O
I	PRP	O
patient	VBP	O
.	.	O

ARMONAIR	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
Pugh	NNP	WHO
score	VBD	WHO
7	CD	WHO
-	:	WHO
9	CD	WHO
)	)	WHO
start	NN	O
AGRYLIN	NNP	O
therapy	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
and	CC	O
monitor	NN	O
frequently	RB	O
for	IN	O
cardiovascular	JJ	O
events	NNS	O
[	JJ	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypoproteinemia	NN	O
,	,	O
200	CD	DOS
to	TO	O
300	CD	DOS
mL	NN	UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
reduce	VB	O
edema	NN	O
and	CC	O
to	TO	O
bring	VB	O
serum	JJ	O
protein	NN	O
values	NNS	O
to	TO	O
normal	JJ	O
.	.	O

Although	IN	O
occasional	JJ	WHO
patients	NNS	WHO
have	VBP	O
responded	VBN	O
to	TO	O
higher	JJR	O
doses	NNS	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	O
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
3	CD	DOS
g.	NN	UNIT
Once	NNP	O
an	DT	O
effective	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
attained	VBN	O
,	,	O
a	DT	O
smooth	JJ	O
blood	NN	O
pressure	NN	O
response	NN	O
occurs	VBZ	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
in	IN	O
12	CD	O
to	TO	O
24	CD	O
hours	NNS	O
.	.	O

Figure	NN	O
16	CD	O

Store	NN	O
unreconstituted	JJ	O
product	NN	O
at	IN	O
20	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
20	CD	DOS
U	NNP	UNIT
/	NNP	O
kg	FW	O
per	IN	FREQ
week	NN	FREQ
.	.	O

Single	NNP	DOS
dose	JJ	UNIT
vial	NN	UNIT
,	,	O
preservative	JJ	O
-	:	O
free	JJ	O
,	,	O
discard	RB	O
unused	JJ	O
portion	NN	O
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
4	CD	DOS
drops	NNS	UNIT
of	IN	O
the	DT	O
suspension	NN	O
should	MD	O
be	VB	O
instilled	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
ear	JJ	O
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
tablet	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

A	DT	O
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
of	IN	O
ActHIB	NNP	O
is	VBZ	O
approved	VBN	O
for	IN	O
intramuscular	JJ	O
administration	NN	O
in	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
,	,	O
2	CD	O
months	NNS	O
through	IN	O
5	CD	O
years	NNS	O
of	IN	O
age	NN	O
as	IN	O
a	DT	O
4	CD	DOS
-	:	O
dose	JJ	O
series	NN	O
.	.	O

There	EX	O
is	VBZ	O
insufficient	JJ	O
data	NNS	O
for	IN	O
dosage	NN	O
recommendation	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
creatinine	JJ	WHO
clearance	NN	WHO
less	JJR	WHO
than	IN	O
10	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
(	(	O
see	VB	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
,	,	O
Heart	NNP	O
Failure	NNP	O
,	,	O
WARNINGS	NNP	O
,	,	O
and	CC	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Monitor	NNP	O
everolimus	JJ	O
whole	JJ	O
blood	NN	O
trough	NN	O
levels	NNS	O
routinely	RB	O
in	IN	O
all	DT	WHO
patients	NNS	WHO
.	.	O

Amikacin	NNP	O
sulfate	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
the	DT	O
following	JJ	O
solutions	NNS	O
:	:	O

However	RB	O
,	,	O
some	DT	O
investigators	NNS	O
feel	VBP	O
that	IN	O
daily	JJ	FREQ
doses	NNS	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
do	VBP	O
not	RB	O
produce	VB	O
any	DT	O
better	JJR	O
results	NNS	O
than	IN	O
a	DT	O
1	CD	DOS
g	NN	UNIT
dose	NN	UNIT
.	.	O

If	IN	O
more	JJR	O
than	IN	O
one	CD	O
topical	JJ	O
ophthalmic	JJ	O
product	NN	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
the	DT	O
different	JJ	O
products	NNS	O
should	MD	O
be	VB	O
instilled	VBN	O
at	IN	O
least	JJS	O
5	CD	O
minutes	NNS	O
apart	RB	O
.	.	O

Activella	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
to	TO	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
vasomotor	NN	O
symptoms	NNS	O
due	JJ	O
to	TO	O
menopause	VB	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
of	IN	O
ALDURAZYME	NNP	O
is	VBZ	O
0.58	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
administered	VBN	O
once	RB	FREQ
weekly	JJ	FREQ
as	IN	O
an	DT	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
.	.	O

Alupent	NNP	O
(	(	O
metaproterenol	JJ	O
sulfate	NN	O
USP	NNP	O
)	)	O
Inhalation	NNP	O
Aerosol	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
children	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
starting	NN	O
dosage	NN	O
for	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
is	VBZ	O
based	VBN	O
upon	IN	O
patients	NNS	WHO
'	POS	WHO
asthma	JJ	WHO
severity	NN	WHO
.	.	O

Multiple	JJ	O
Myeloma	NNP	O
:	:	O
The	DT	O
usual	JJ	O
oral	JJ	O
dose	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
(	(	O
3	CD	DOS
tablets	NNS	UNIT
)	)	O
daily	RB	FREQ
.	.	O

Ordinarily	RB	O
,	,	O
an	DT	O
intravenous	JJ	O
dose	NN	O
of	IN	O
65	CD	DOS
mg	NNS	UNIT
to	TO	O
0.5	CD	DOS
g	NN	UNIT
may	MD	O
be	VB	O
given	VBN	O
to	TO	O
a	DT	O
child	NN	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

Dosage	NN	O
for	IN	O
Adults	NNP	WHO
-	:	O
one	CD	DOS
0.5	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
administered	VBD	O
approximately	RB	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
chemotherapy	NN	O
.	.	O

Doses	NNS	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
to	TO	O
1000	CD	DOS
mg	NN	UNIT
of	IN	O
DEPO	NNP	O
-	:	O
PROVERA	NNP	O
Sterile	NNP	O
Aqueous	NNP	O
Suspension	NNP	O
per	IN	FREQ
week	NN	FREQ
are	VBP	O
recommended	VBN	O
initially	RB	O
.	.	O

In	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
with	IN	O
Amikacin	NNP	O
Sulfate	NNP	O
Injection	NNP	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
solutions	NNS	O
aged	VBD	O
for	IN	O
60	CD	PER
days	NNS	PER
at	IN	O
4°C	CD	O
and	CC	O
then	RB	O
stored	VBD	O
at	IN	O
25°C	CD	O
had	VBD	O
utility	NN	O
times	NNS	O
of	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
(	(	WHO
age	NN	WHO
≥	VBZ	WHO
65	CD	WHO
years	NNS	WHO
)	)	WHO
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
administered	VBD	O
should	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	O
for	IN	O
those	DT	O
requiring	VBG	O
fluid	JJ	O
restriction	NN	O
(	(	O
see	VB	O
Tables	NNP	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
.	.	O

More	JJR	O
than	IN	O
two	CD	DOS
sequential	JJ	UNIT
doses	NNS	UNIT
of	IN	O
epinephrine	NN	O
should	MD	O
only	RB	O
be	VB	O
administered	VBN	O
under	IN	O
direct	JJ	O
medical	JJ	O
supervision	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

If	IN	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
patients	NNS	WHO
receiving	VBG	WHO
the	DT	WHO
lowest	JJS	WHO
available	JJ	WHO
strength	NN	WHO
,	,	O
administer	NN	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

Lipid	JJ	O
emulsion	NN	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
3	CD	DOS
g	NNS	UNIT
fat	JJ	O
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
infused	VBD	O
simultaneously	RB	O
with	IN	O
Aminosyn	NNP	O
II	NNP	O
4.25	CD	O
%	NN	O
in	IN	O
25	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
Y	NNP	O
-	:	O
connector	NN	O
located	VBN	O
near	IN	O
the	DT	O
infusion	NN	O
site	NN	O
,	,	O
using	VBG	O
separate	JJ	O
flow	NN	O
controls	NNS	O
for	IN	O
each	DT	O
solution	NN	O
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
ALDOMET	NNP	O
(	(	O
methyldopa	NN	O
)	)	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	DOS
g	NNS	UNIT
in	IN	O
two	CD	DOS
to	TO	O
four	CD	DOS
doses	NNS	UNIT
.	.	O

During	IN	O
withdrawal	NN	O
,	,	O
some	DT	O
patients	NNS	O
may	MD	O
experience	VB	O
symptoms	NNS	O
of	IN	O
systemic	JJ	O
corticosteroid	NN	O
withdrawal	NN	O
;	:	O
e.g	NN	O
.	.	O

6	CD	O

Adult	NN	WHO
patients	NNS	WHO
whose	WP$	WHO
disease	NN	WHO
is	VBZ	WHO
very	RB	WHO
severe	JJ	WHO
with	IN	WHO
scarring	NN	WHO
or	CC	O
is	VBZ	O
primarily	RB	O
manifested	VBN	O
on	IN	O
the	DT	O
trunk	NN	O
may	MD	O
require	VB	O
dose	NN	O
adjustments	NNS	O
up	IN	O
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

(	(	O
10	CD	O
)	)	O
Danger	NNP	O
label	NN	O
:	:	O
The	DT	O
unit	NN	O
should	MD	O
have	VB	O
a	DT	O
label	NN	O
prominently	RB	O
displayed	VBD	O
which	WDT	O
reads	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

In	IN	O
children	NNS	WHO
with	IN	WHO
ADHD	NNP	WHO
who	WP	WHO
are	VBP	WHO
6	CD	WHO
-	:	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
are	VBP	WHO
either	DT	WHO
starting	VBG	WHO
treatment	NN	WHO
for	IN	WHO
the	DT	WHO
first	JJ	WHO
time	NN	WHO
or	CC	WHO
switching	VBG	WHO
from	IN	WHO
another	DT	WHO
medication	NN	WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
or	CC	O
10	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
CYSTARAN	NNP	O
in	IN	O
each	DT	O
eye	NN	O
,	,	O
every	DT	FREQ
waking	VBG	FREQ
hour	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
for	IN	O
adult	NN	WHO
schizophrenic	JJ	WHO
patients	NNS	WHO
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
with	IN	O
a	DT	O
gradual	JJ	O
increment	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
800	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
if	IN	O
necessary	JJ	O
.	.	O

Apply	NNP	O
twice	JJ	FREQ
daily	RB	FREQ
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
,	,	O
for	IN	O
3	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
then	RB	O
withhold	VBD	O
use	NN	O
for	IN	O
4	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

If	IN	O
patients	NNS	O
require	VBP	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
a	DT	O
moderate	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitor	NN	O
,	,	O
reduce	VB	O
the	DT	O
AFINITOR	NNP	O
dose	NN	O
to	TO	O
2.5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Addition	NN	O
of	IN	O
iron	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	WHO
infant	NN	WHO
than	IN	O
the	DT	WHO
adult	NN	WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
for	IN	O
the	DT	O
growing	VBG	O
infant	NN	O
.	.	O

The	DT	O
lotion	NN	O
may	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
to	TO	O
the	DT	O
specified	VBN	O
lesions	NNS	O
,	,	O
particularly	RB	O
to	TO	O
those	DT	O
in	IN	O
hairy	JJ	O
areas	NNS	O
,	,	O
two	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
.	.	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
clinical	JJ	O
data	NNS	O
with	IN	O
this	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
strong	JJ	WHO
CYP3A4	NNP	WHO
/	NNP	O
PgP	NNP	O
inducers	NNS	O
.	.	O

A	DT	O
mixture	NN	O
of	IN	O
Aminosyn	NNP	O
II	NNP	O
and	CC	O
dextrose	RB	O
diluted	VBN	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
and	CC	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
is	VBZ	O
suitable	JJ	O
for	IN	O
administration	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAPHRIS	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
given	VBN	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Reconstituted	VBN	O
AFSTYLA	NNP	O
may	MD	O
be	VB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
,	,	O
for	IN	O
up	IN	O
to	TO	O
4	CD	O
hours	NNS	O
.	.	O

The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
Bumex	NNP	O
(	(	O
bumetanide	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	DOS
mg	NNS	UNIT
and	CC	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
is	VBZ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

Usual	JJ	O
regimens	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
ALTACE	NNP	O
may	MD	O
be	VB	O
followed	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
estimated	VBN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
>	VBD	WHO
40	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

Subsequent	JJ	O
dose	NN	O
increases	NNS	O
,	,	O
if	IN	O
needed	VBN	O
,	,	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
increments	NNS	O
.	.	O

It	PRP	O
has	VBZ	O
usually	RB	O
been	VBN	O
found	VBN	O
that	IN	O
a	DT	O
dosage	NN	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
per	IN	O
24	CD	O
hours	NNS	O
does	VBZ	O
not	RB	O
produce	VB	O
an	DT	O
increased	JJ	O
effect	NN	O
.	.	O

A	DT	O
patient	NN	WHO
who	WP	WHO
becomes	VBZ	WHO
hypotensive	VBP	WHO
at	IN	WHO
this	DT	WHO
dose	NN	WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
1.25	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
=	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
x	NN	O
Desired	NNP	O
Factor	NNP	O
VIII	NNP	O
rise	NN	O
(	(	O
IU	NNP	O
/	NNP	O
dL	VBD	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
x	VBZ	O
0.5	CD	DOS
(	(	O
IU	NNP	O
/	NNP	O
kg	FW	O
per	IN	O
IU	NNP	O
/	NNP	O
dL	NN	O
)	)	O

The	DT	O
solution	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
is	VBZ	O
prepared	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
500	CD	DOS
mg	NN	UNIT
vial	NN	UNIT
to	TO	O
100	CD	DOS
or	CC	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
or	CC	O
any	DT	O
of	IN	O
the	DT	O
compatible	JJ	O
solutions	NNS	O
listed	VBN	O
below	IN	O
.	.	O

A	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
dose	NN	UNIT
of	IN	O
ACTHREL®	NNP	O
at	IN	O
1	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
testing	NN	O
of	IN	O
pituitary	JJ	O
corticotrophin	NN	O
function	NN	O
.	.	O

Figure	NN	O
2	CD	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
On	IN	O
-	:	O
demand	NN	O
Treatment	NNP	O
and	CC	O
Control	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

AMEVIVE®	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
the	DT	O
counts	NNS	O
remain	VBP	O
below	IN	O
250	CD	DOS
cells	NNS	UNIT
/	JJ	O
µL	NNP	O
for	IN	O
one	CD	PER
month	NN	PER
[	VBD	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
ALPHAGAN®	NNP	O
P	NNP	O
(	(	O
brimonidine	JJ	O
tartrate	NN	O
)	)	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severely	RB	WHO
impaired	JJ	WHO
hepatic	JJ	WHO
function	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Class	NNP	WHO
C	NNP	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mcg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

ONE	CD	DOS
APPLICATION	NNP	UNIT
IS	NNP	O
GENERALLY	NNP	O
CURATIVE	NNP	O
.	.	O

Store	NN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Part	NN	O
of	IN	O
the	DT	O
nonprotein	JJ	O
caloric	JJ	O
requirement	NN	O
may	MD	O
be	VB	O
provided	VBN	O
as	IN	O
lipid	JJ	O
emulsion	NN	O
administered	VBD	O
concurrently	RB	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
60	CD	O
%	NN	O
of	IN	O
daily	JJ	FREQ
calories	NNS	O
at	IN	O
a	DT	O
dose	NN	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
g	JJ	UNIT
fat	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Begin	NNP	O
whole	JJ	O
body	NN	O
planar	JJ	O
scintigraphy	NN	O
imaging	VBG	O
24	CD	O
±	JJ	O
6	CD	O
hours	NNS	O
following	VBG	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
.	.	O

A	DT	O
semipermeable	JJ	O
dressing	NN	O
is	VBZ	O
one	CD	O
that	WDT	O
allows	VBZ	O
for	IN	O
the	DT	O
passage	NN	O
of	IN	O
air	NN	O
but	CC	O
does	VBZ	O
not	RB	O
allow	VB	O
for	IN	O
the	DT	O
passage	NN	O
of	IN	O
fluids	NNS	O
.	.	O

Initial	JJ	O
dose	NN	O
:	:	O
Give	VB	O
0.05	CD	DOS
to	TO	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
as	IN	O
a	DT	O
rapid	JJ	O
IV	NNP	O
bolus	NN	O
given	VBN	O
either	CC	O
centrally	RB	O
or	CC	O
peripherally	RB	O
.	.	O

ACAM2000	NNP	O
is	VBZ	O
reconstituted	VBN	O
by	IN	O
addition	NN	O
of	IN	O
0.3	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
to	TO	O
the	DT	O
vial	JJ	O
containing	NN	O
lyophilized	VBN	O
vaccine	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postoperative	JJ	O
inflammation	NN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
undergone	VBN	WHO
cataract	JJ	WHO
extraction	NN	WHO
,	,	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
ACULAR®	NNP	O
ophthalmic	JJ	O
solution	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
cataract	NN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	PER
weeks	NNS	PER
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
.	.	O

When	WRB	O
in	IN	O
the	DT	O
judgment	NN	O
of	IN	O
the	DT	O
clinician	NN	O
a	DT	O
lower	JJR	O
initial	JJ	O
dose	NN	O
is	VBZ	O
appropriate	JJ	O
,	,	O
patients	NNS	O
may	MD	O
begin	VB	O
treatment	NN	O
with	IN	O
5	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
UPTRAVI	NNP	O
is	VBZ	O
200	CD	DOS
micrograms	NNS	UNIT
(	(	O
mcg	NN	O
)	)	O
given	VBN	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

(	(	O
Use	NNP	O
only	RB	O
one	CD	DOS
filter	NN	UNIT
per	IN	O
vial	NN	O
of	IN	O
AmBisome	NNP	O
.	.	O
)	)	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	DOS
-	:	O
60	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
single	JJ	DOS
doses	NNS	UNIT
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Subsequent	JJ	O
dose	NN	O
increases	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
5	CD	DOS
mg	NN	UNIT
increments	NNS	UNIT
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ARAVA	NNP	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLECTOR	NNP	O
PATCH	NNP	O
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
patch	NN	UNIT
to	TO	O
the	DT	O
most	RBS	O
painful	JJ	O
area	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
daily	RB	FREQ
dose	NN	O
of	IN	O
methyldopa	NN	O
is	VBZ	O
3	CD	DOS
g	NN	UNIT
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
15	CD	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
25	CD	O
two	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ADVICOR	NNP	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
by	IN	O
more	JJR	O
than	IN	O
500	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
(	(	O
based	VBN	O
on	IN	O
the	DT	O
NIASPAN	NNP	O
component	NN	O
)	)	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

Hoogstraten	NNP	O
et	CC	O
al	NNS	O
have	VBP	O
started	VBN	O
treatment	NN	O
with	IN	O
0.15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Initial	JJ	O
amino	NN	O
acid	JJ	O
dosage	NN	O
levels	NNS	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
in	IN	O
increments	NNS	O
of	IN	O
0.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
to	TO	O
approximate	VB	O
desired	JJ	O
intake	NN	O
levels	NNS	O
.	.	O

Doses	NNS	O
of	IN	O
ADVICOR	NNP	O
greater	JJR	O
than	IN	O
2000	CD	DOS
mg	NN	UNIT
/	VBD	O
40	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Consider	VB	O
a	DT	O
starting	NN	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
,	,	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
when	WRB	O
initiating	VBG	O
Adempas	NNP	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
strong	JJ	WHO
cytochrome	NN	WHO
P450	NNP	WHO
(	(	O
CYP	NNP	O
)	)	O
and	CC	O
P	NNP	O
-	:	O
glycoprotein	NN	O
/	JJ	O
breast	NN	O
cancer	NN	O
resistance	NN	O
protein	NN	O
(	(	O
P	NNP	O
-	:	O
gp	NN	O
/	NNP	O
BCRP	NNP	O
)	)	O
inhibitors	NNS	O
such	JJ	O
as	IN	O
azole	JJ	O
antimycotics	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
itraconazole	NN	O
)	)	O
or	CC	O
HIV	NNP	O
protease	NN	O
inhibitors	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
ritonavir	NN	O
)	)	O
.	.	O

Luminescence	NN	O
appears	VBZ	O
in	IN	O
the	DT	O
retina	NN	O
and	CC	O
choroidal	NN	O
vessels	NNS	O
in	IN	O
9	CD	O
to	TO	O
14	CD	O
seconds	NNS	O
and	CC	O
can	MD	O
be	VB	O
observed	VBN	O
by	IN	O
standard	JJ	O
viewing	VBG	O
equipment	NN	O
.	.	O

When	WRB	O
amikacin	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
newborns	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
box	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
be	VB	O
administered	VBN	O
initially	RB	O
to	TO	O
be	VB	O
followed	VBN	O
with	IN	O
7.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

In	IN	O
adults	NNS	WHO
,	,	O
strongly	RB	O
hypertonic	JJ	O
admixtures	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	VB	O
may	MD	O
be	VB	O
safely	RB	O
administered	VBN	O
only	RB	O
by	IN	O
continuous	JJ	O
infusion	NN	O
through	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
catheter	NN	O
with	IN	O
the	DT	O
tip	NN	O
located	VBN	O
in	IN	O
the	DT	O
superior	JJ	O
vena	NN	O
cava	NN	O
.	.	O

ALDACTONE	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
for	IN	O
four	CD	PER
days	NNS	PER
.	.	O

If	IN	O
the	DT	O
diuretic	NN	O
can	MD	O
not	RB	O
be	VB	O
discontinued	VBN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
ACCUPRIL	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
careful	JJ	O
medical	JJ	O
supervision	NN	O
for	IN	O
several	JJ	PER
hours	NNS	PER
and	CC	O
until	IN	O
blood	NN	O
pressure	NN	O
has	VBZ	O
stabilized	VBN	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
BLOCADREN	NNP	O
(	(	O
timolol	NN	O
)	)	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
.	.	O

Ambien	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
and	CC	O
should	MD	O
not	RB	O
be	VB	O
readministered	VBN	O
during	IN	O
the	DT	O
same	JJ	O
night	NN	O
.	.	O

The	DT	O
amount	NN	O
usually	RB	O
administered	VBN	O
is	VBZ	O
500	CD	DOS
to	TO	O
1000	CD	DOS
mL	NN	UNIT
.	.	O

To	TO	O
prepare	VB	O
ActHIB	NNP	O
vaccine	NN	O
,	,	O
withdraw	JJ	O
0.6	CD	DOS
mL	NN	UNIT
of	IN	O
saline	JJ	O
diluent	NN	O
(	(	O
0.4	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
)	)	O
and	CC	O
inject	VB	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
ActHIB	NNP	O
vaccine	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Akten™	NNP	O
(	(	O
lidocaine	JJ	O
hydrochloride	NN	O
ophthalmic	JJ	O
gel	NN	O
)	)	O
is	VBZ	O
2	CD	DOS
drops	NNS	UNIT
applied	VBN	O
to	TO	O
the	DT	O
ocular	JJ	O
surface	NN	O
in	IN	O
the	DT	O
area	NN	O
of	IN	O
the	DT	O
planned	JJ	O
procedure	NN	O
.	.	O

If	IN	O
at	IN	O
any	DT	O
time	NN	O
,	,	O
the	DT	O
patient	NN	O
has	VBZ	O
symptoms	NNS	O
of	IN	O
hypotension	NN	O
,	,	O
decrease	VB	O
the	DT	O
dosage	NN	O
by	IN	O
0.5	CD	DOS
mg	NNS	UNIT
taken	VBN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

During	IN	O
titration	NN	O
,	,	O
patients	NNS	O
can	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
use	VB	O
multiples	NNS	O
of	IN	O
100	CD	DOS
mcg	JJ	UNIT
tablets	NNS	UNIT
and	CC	O
/	NNP	O
or	CC	O
200	CD	DOS
mcg	JJ	UNIT
tablets	NNS	UNIT
for	IN	O
any	DT	O
single	JJ	O
dose	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
ADVATE	NN	O
Dosing	VBG	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O
in	IN	O
Adults	NNP	WHO
and	CC	WHO
Children	NNP	WHO

For	IN	O
children	NNS	WHO
over	IN	WHO
8	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
up	IN	O
to	TO	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O

The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
take	VB	O
supplemental	JJ	O
vitamin	NN	O
E	NNP	O
since	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
content	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
exceeds	VBZ	O
the	DT	O
Reference	NNP	O
Daily	NNP	FREQ
Intake	NNP	O
(	(	O
adults	NNS	WHO
30	CD	O
IU	NNP	O
,	,	O
pediatrics	NNS	WHO
approximately	RB	O
10	CD	DOS
IU	NNP	UNIT
)	)	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
0.25	CD	O
percent	NN	O
Preservative	NNP	O
-	:	O
free	JJ	O
TIMOPTIC	NNP	O
in	IN	O
OCUDOSE	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
administered	VBD	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

In	IN	O
hyperammonemic	JJ	WHO
infants	NNS	WHO
with	IN	WHO
suspected	JJ	WHO
,	,	WHO
but	CC	WHO
unconfirmed	JJ	WHO
urea	JJ	WHO
cycle	NN	WHO
disorders	NNS	WHO
,	,	O
intravenous	JJ	O
arginine	NN	O
should	MD	O
be	VB	O
given	VBN	O
(	(	O
6	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
Arginine	NNP	O
HCl	NNP	O
Injection	NNP	O
10	CD	O
%	NN	O
,	,	O
over	IN	O
90	CD	O
minutes	NNS	O
followed	VBN	O
by	IN	O
the	DT	O
same	JJ	O
dose	JJ	O
given	VBN	O
as	IN	O
a	DT	O
maintenance	NN	O
infusion	NN	O
over	IN	O
24	CD	O
hours	NNS	O
)	)	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
(	(	O
amprenavir	JJ	O
capsules	NNS	O
)	)	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
1,200	CD	DOS
mg	NN	UNIT
(	(	O
twenty	JJ	DOS
-	:	O
four	CD	DOS
50	CD	DOS
-	:	O
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
.	.	O

If	IN	O
adequate	JJ	O
analgesia	NN	O
is	VBZ	O
not	RB	O
obtained	VBN	O
with	IN	O
a	DT	O
400	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
,	,	O
the	DT	O
next	JJ	O
titration	NN	O
step	NN	O
is	VBZ	O
600	CD	DOS
mcg	NN	UNIT
.	.	O

Such	JJ	O
infusates	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
dilutions	NNS	O
of	IN	O
Aminosyn	NNP	O
-	:	O
HF	$	O
8	CD	O
%	NN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
or	CC	O
5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
to	TO	O
prepare	VB	O
isotonic	JJ	O
or	CC	O
slightly	RB	O
hypertonic	JJ	O
solutions	NNS	O
for	IN	O
peripheral	JJ	O
infusion	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
to	TO	WHO
moderate	VB	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
maximum	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2.5	CD	DOS
mg	NNS	UNIT
over	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
and	CC	O
a	DT	O
1	CD	DOS
-	:	O
mg	NN	O
starting	VBG	O
dose	NN	O
is	VBZ	O
recommended	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Each	DT	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
contains	VBZ	O
:	:	O

If	IN	O
CD4+	NNP	O
T	NNP	O
lymphocyte	NN	O
counts	NNS	O
are	VBP	O
below	IN	O
250	CD	DOS
cells	NNS	UNIT
/	JJ	O
µL	NNP	O
,	,	O
AMEVIVE®	NNP	O
dosing	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
and	CC	O
weekly	JJ	FREQ
monitoring	NN	O
instituted	VBN	O
.	.	O

Topical	JJ	O
corticosteroids	NNS	O
are	VBP	O
generally	RB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
from	IN	O
two	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

COVERA	NNP	O
-	:	O
HS	NN	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
wick	NN	O
may	MD	O
be	VB	O
removed	VBN	O
after	IN	O
24	CD	O
hours	NNS	O
but	CC	O
the	DT	O
patient	NN	O
should	MD	O
continue	VB	O
to	TO	O
instill	VB	O
5	CD	DOS
drops	NNS	UNIT
of	IN	O
Acetic	NNP	O
Acid	NNP	O
Otic	NNP	O
Solution	NNP	O
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
thereafter	RB	O
,	,	O
for	IN	O
as	RB	O
long	RB	O
as	IN	O
indicated	VBN	O
.	.	O

The	DT	O
daily	JJ	FREQ
requirements	NNS	O
of	IN	O
the	DT	WHO
stable	JJ	WHO
,	,	O
nonhypermetabolic	JJ	WHO
adult	NN	WHO
patient	NN	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
are	VBP	O
approximately	RB	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	NN	O
,	,	O
and	CC	O
2500	CD	DOS
to	TO	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACCOLATE	NNP	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

USE	NNP	O
ONLY	NNP	O
THE	NNP	O
ADRENALIN	NNP	O
1	CD	DOS
ML	NNP	UNIT
SINGLE	NNP	O
-	:	O
USE	NN	O
VIAL	NNP	O
FOR	NNP	O
OPHTHALMIC	NNP	O
USE	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
administered	VBN	WHO
anesthetic	JJ	WHO
(	(	O
induction	NN	O
)	)	O
dosages	NNS	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
that	IN	O
qualified	JJ	O
personnel	NNS	O
and	CC	O
adequate	JJ	O
facilities	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
intraoperative	JJ	O
and	CC	O
postoperative	JJ	O
respiratory	NN	O
depression	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Nongonococcal	JJ	O
urethritis	NN	O
(	(	O
NGU	NNP	O
)	)	O
caused	VBN	O
by	IN	O
C.	NNP	O
trachomatis	NN	O
and	CC	O
U.	NNP	O
urealyticum	NN	O
:	:	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PIPRACIL	NNP	O
(	(	O
piperacillin	JJ	O
sodium	NN	O
)	)	O
for	IN	O
serious	JJ	O
infections	NNS	O
is	VBZ	O
3	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
given	VBN	O
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
a	DT	O
-	:	O
20	CD	O
to	TO	O
30	CD	O
-	:	O
minute	NN	O
infusion	NN	O
.	.	O

If	IN	O
persistent	JJ	O
hypokalemia	NN	O
is	VBZ	O
documented	VBN	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
15	CD	DOS
mg	NNS	UNIT
,	,	O
then	RB	O
20	CD	DOS
mg	NNS	UNIT
,	,	O
with	IN	O
careful	JJ	O
monitoring	NN	O
of	IN	O
electrolytes	NNS	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
Children	NNP	WHO
30	CD	WHO
kg	NN	WHO
(	(	WHO
66	CD	WHO
lbs	NN	WHO
)	)	WHO
or	CC	WHO
more	JJR	WHO
:	:	O
0.3	CD	DOS
to	TO	O
0.5	CD	DOS
mg	NN	UNIT
(	(	O
0.3	CD	DOS
mL	NN	UNIT
to	TO	O
0.5	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
undiluted	JJ	O
Adrenalin®	NNP	O
administered	VBD	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
in	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
(	(	O
0.5	CD	DOS
mL	NN	UNIT
)	)	O
per	IN	O
injection	NN	O
,	,	O
repeated	VBN	O
every	DT	FREQ
5	CD	FREQ
to	TO	O
10	CD	FREQ
minutes	NNS	FREQ
as	IN	O
necessary	JJ	O
.	.	O

Use	NNP	O
another	DT	O
rabeprazole	NN	O
formulation	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
year	NN	WHO
to	TO	WHO
less	JJR	WHO
than	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

ADIPEX	NNP	O
-	:	O
P®	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
≤	VBP	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	WHO
and	CC	O
either	DT	O
5	CD	DOS
or	CC	O
10	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	WHO
,	,	O
taken	VBN	O
only	RB	O
once	RB	O
per	IN	O
night	NN	O
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7	CD	O
–	JJ	O
8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
stable	JJ	WHO
coronary	JJ	WHO
artery	NN	WHO
disease	NN	WHO
,	,	O
ACEON	NNP	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
4	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
2	CD	PER
weeks	NNS	PER
,	,	O
and	CC	O
then	RB	O
increased	VBD	O
as	IN	O
tolerated	VBN	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
8	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Syphilis	NN	O
of	IN	O
more	JJR	O
than	IN	O
one	CD	O
year	NN	O
's	POS	O
duration	NN	O
:	:	O
Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
allergic	JJ	WHO
to	TO	WHO
penicillin	VB	WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
doxycycline	JJ	O
100	CD	DOS
mg	NN	UNIT
by	IN	O
mouth	NN	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
4	CD	PER
weeks	NNS	PER
.	.	O

Patients	NNS	WHO
at	IN	WHO
increased	VBN	WHO
risk	NN	WHO
for	IN	WHO
hypoglycemia	NN	WHO
(	(	O
e.g	UH	O
,	,	O
the	DT	WHO
elderly	JJ	WHO
or	CC	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
)	)	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
1	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
400	CD	DOS
mcg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
when	WRB	WHO
starting	VBG	WHO
therapy	NN	WHO
with	IN	WHO
AllerNaze	NNP	WHO
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
in	IN	O
cases	NNS	O
where	WRB	O
a	DT	O
faster	RBR	O
onset	NN	O
of	IN	O
relief	NN	O
is	VBZ	O
desirable	JJ	O
.	.	O

Each	DT	O
gram	NN	O
of	IN	O
dextrose	JJ	O
provides	VBZ	O
approximately	RB	O
3.4	CD	O
kcal	JJ	O
.	.	O

For	IN	O
maintenance	NN	O
therapy	NN	O
at	IN	O
dosages	NNS	O
of	IN	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
less	JJR	O
,	,	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
at	IN	O
bedtime	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

A	DT	O
2.5	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
of	IN	O
albuterol	NN	O
provided	VBN	O
by	IN	O
a	DT	O
higher	JJR	O
concentration	NN	O
product	NN	O
(	(	O
2.5	CD	DOS
mg	NN	UNIT
albuterol	NN	O
per	IN	O
3	CD	DOS
mL	NN	UNIT
)	)	O
may	MD	O
be	VB	O
more	JJR	O
appropriate	JJ	O
for	IN	O
treating	VBG	O
acute	JJ	O
exacerbations	NNS	O
,	,	O
particularly	RB	O
in	IN	O
children	NNS	WHO
6	CD	WHO
years	NNS	WHO
old	JJ	WHO
and	CC	WHO
above	JJ	WHO
.	.	O

Combination	NNP	O
therapy	NN	O
with	IN	O
NIASPAN	NNP	O
and	CC	O
lovastatin	NN	O
should	MD	O
not	RB	O
exceed	VB	O
doses	NNS	O
of	IN	O
2000	CD	DOS
mg	NN	UNIT
and	CC	O
40	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
,	,	O
respectively	RB	O
.	.	O

0.14	CD	DOS
(	(	O
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
)	)	O
x	FW	O
total	JJ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
/	FW	O
Adenoscan	JJ	O
concentration	NN	O
(	(	O
3mg	CD	DOS
/	NNP	O
mL	NN	O
)	)	O
=	VBZ	O
Infusion	NNP	O
rate	NN	O
(	(	O
mL	JJ	O
/	NNP	O
min	NN	O
)	)	O

If	IN	O
such	JJ	O
circumstances	NNS	O
are	VBP	O
suspected	VBN	O
to	TO	O
be	VB	O
present	JJ	O
,	,	O
the	DT	O
initial	JJ	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
1.25	CD	DOS
mg	JJ	UNIT
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Osserman	NNP	O
and	CC	O
Takatsuki	NNP	O
have	VBP	O
used	VBN	O
an	DT	O
initial	JJ	O
course	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
7	CD	O
to	TO	O
10	CD	O
days	NNS	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
who	WP	WHO
have	VBP	WHO
tolerated	VBN	WHO
AGRYLIN	NNP	WHO
therapy	NN	O
for	IN	O
one	CD	PER
week	NN	PER
may	MD	O
have	VB	O
their	PRP$	O
dose	NN	O
increased	VBN	O
.	.	O

Adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
take	VB	O
supplemental	JJ	O
vitamin	NN	O
E	NNP	O
since	IN	O
the	DT	O
vitamin	NN	O
E	NNP	O
content	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
exceeds	VBZ	O
the	DT	O
Reference	NNP	O
Daily	NNP	FREQ
Intake	NNP	O
(	(	O
adults	NNS	WHO
30	CD	O
IU	NNP	O
,	,	O
pediatrics	NNS	WHO
approximately	RB	O
10	CD	DOS
IU	NNP	UNIT
)	)	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

Usual	NNP	O
dose	VBD	O
5	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

To	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
constipation	NN	O
,	,	O
alosetron	NN	O
hydrochloride	NN	O
tablets	NNS	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Each	DT	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
mixed	JJ	O
under	IN	O
sterile	JJ	O
conditions	NNS	O
with	IN	O
832	CD	DOS
mL	NNS	UNIT
of	IN	O
Dextrose	NNP	O
70	CD	O
%	NN	O
will	MD	O
provide	VB	O
a	DT	O
solution	NN	O
of	IN	O
1.95	CD	O
%	NN	O
of	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
in	IN	O
44	CD	O
%	NN	O
dextrose	NN	O
.	.	O

There	EX	O
are	VBP	O
inadequate	JJ	O
data	NNS	O
to	TO	O
make	VB	O
dosage	NN	O
recommendations	NNS	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
in	IN	O
patients	NNS	WHO
below	IN	WHO
the	DT	WHO
age	NN	WHO
of	IN	WHO
ten	NN	WHO
(	(	WHO
10	CD	WHO
)	)	WHO
years	NNS	WHO
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IRESSA	NNP	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
study	NN	O
with	IN	O
AGENERASE	NNP	O
Capsules	NNP	O
,	,	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
ranging	VBG	WHO
from	IN	WHO
5	CD	WHO
to	TO	WHO
8	CD	WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
of	IN	O
513	CD	DOS
mg	NN	UNIT
(	(	O
34	CD	DOS
mL	NN	UNIT
)	)	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
and	CC	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
ranging	VBG	WHO
from	IN	WHO
9	CD	WHO
to	TO	WHO
12	CD	WHO
should	MD	O
receive	VB	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
of	IN	O
342	CD	DOS
mg	NN	UNIT
(	(	O
23	CD	DOS
mL	NN	UNIT
)	)	O
twice	RB	FREQ
daily	JJ	FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Hepatic	JJ	O
Insufficiency	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
for	IN	O
overweight	NN	WHO
adults	NNS	WHO
18	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
1	CD	DOS
60	CD	DOS
-	:	O
mg	NN	UNIT
capsule	NN	UNIT
with	IN	O
each	DT	O
meal	NN	O
containing	VBG	O
fat	NN	O
.	.	O

For	IN	O
recurrence	NN	O
of	IN	O
severe	JJ	O
neutropenia	NN	O
or	CC	O
severe	JJ	O
sensory	NN	O
neuropathy	NN	O
,	,	O
additional	JJ	O
dose	NN	O
reduction	NN	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
180	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
.	.	O

Only	RB	O
in	IN	O
rare	JJ	O
cases	NNS	O
will	MD	O
it	PRP	O
be	VB	O
necessary	JJ	O
to	TO	O
exceed	VB	O
a	DT	O
total	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

As	IN	O
Acetadote	NNP	O
is	VBZ	O
hyperosmolar	JJ	O
(	(	O
2600	CD	DOS
mOsmol	NN	UNIT
/	NNP	O
L	NNP	O
)	)	O
,	,	O
caution	NN	O
is	VBZ	O
advised	VBN	O
when	WRB	O
the	DT	O
diluent	NN	O
volume	NN	O
is	VBZ	O
decreased	VBN	O
as	IN	O
the	DT	O
hyperosmolarity	NN	O
of	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
increased	VBN	O
.	.	O

XTAMPZA	NN	O
ER	NNP	O
is	VBZ	O
administered	VBN	O
,	,	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
,	,	O
and	CC	O
must	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

If	IN	O
you	PRP	O
stop	VBP	O
using	VBG	O
alli	NN	O
(	(	O
orlistat	JJ	O
60	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
continue	VBP	O
with	IN	O
a	DT	O
diet	JJ	O
and	CC	O
exercise	JJ	O
program	NN	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
four	CD	DOS
episodes	NNS	UNIT
of	IN	O
breakthrough	NN	O
pain	NN	O
are	VBP	O
experienced	VBN	O
per	IN	O
day	NN	O
,	,	O
re	VB	O
-	:	O
evaluate	VB	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
long	JJ	O
-	:	O
acting	VBG	O
opioid	NN	O
used	VBN	O
for	IN	O
persistent	JJ	O
underlying	JJ	O
cancer	NN	O
pain	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
ACEON	NNP	O
for	IN	O
the	DT	WHO
elderly	JJ	WHO
is	VBZ	O
4	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
,	,	O
given	VBN	O
in	IN	O
one	CD	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

For	IN	O
peripheral	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
of	IN	O
total	JJ	O
amino	NN	O
acids	NNS	O
will	MD	O
reduce	VB	O
protein	JJ	O
catabolism	NN	O
.	.	O

Once	RB	O
a	DT	O
successful	JJ	O
dose	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
(	(	O
i.e	FW	O
,	,	O
an	DT	O
average	JJ	O
episode	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
a	DT	O
single	JJ	O
unit	NN	O
)	)	O
,	,	O
patients	NNS	O
should	MD	O
limit	VB	O
consumption	NN	O
to	TO	O
four	CD	DOS
or	CC	O
fewer	JJR	DOS
units	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
benzyl	NN	O
alcohol	NN	O
in	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
may	MD	O
cause	VB	O
serious	JJ	O
adverse	JJ	O
reactions	NNS	O
in	IN	O
premature	NN	WHO
or	CC	WHO
low	JJ	WHO
birth	NN	WHO
-	:	WHO
weight	NN	WHO
infants	NNS	WHO
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Examples	NNS	O
of	IN	O
cartridge	NN	O
combinations	NNS	O
for	IN	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
24	CD	DOS
units	NNS	UNIT
are	VBP	O
shown	VBN	O
in	IN	O
Figure	NNP	O
1	CD	O
.	.	O

In	IN	O
many	JJ	WHO
patients	NNS	WHO
,	,	O
provision	NN	O
of	IN	O
adequate	JJ	O
calories	NNS	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
hypertonic	JJ	O
dextrose	NN	O
may	MD	O
require	VB	O
the	DT	O
administration	NN	O
of	IN	O
exogenous	JJ	O
insulin	NN	O
to	TO	O
prevent	VB	O
hyperglycemia	NN	O
and	CC	O
glycosuria	NN	O
.	.	O

If	IN	O
changes	NNS	O
are	VBP	O
not	RB	O
controlled	VBN	O
after	IN	O
three	CD	DOS
bolus	NN	UNIT
doses	NNS	UNIT
given	VBN	O
over	RP	O
a	DT	O
five	CD	O
minute	NN	O
period	NN	O
,	,	O
a	DT	O
barbiturate	NN	O
,	,	O
vasodilator	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
inhalation	NN	O
agent	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
PRESTALIA	NNP	O
is	VBZ	O
3.5	CD	DOS
/	JJ	O
2.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Flushing	VBG	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
may	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
frequency	NN	O
or	CC	O
severity	NN	O
by	IN	O
pretreatment	NN	O
with	IN	O
aspirin	NN	O
up	RB	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
325	CD	DOS
mg	NN	UNIT
(	(	O
taken	VBN	O
up	RP	O
to	TO	O
approximately	RB	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
ADVICOR	NNP	O
dose	NN	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BONIVA	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
is	VBZ	O
3	CD	DOS
mg	NN	UNIT
every	DT	FREQ
3	CD	FREQ
months	NNS	FREQ
administered	VBN	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
15	CD	O
to	TO	O
30	CD	O
seconds	NNS	O
.	.	O

Depending	VBG	O
upon	IN	O
tolerance	NN	O
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
100	CD	DOS
mg	NNS	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
by	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
first	JJ	PER
week	NN	PER
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
as	IN	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
Xiidra	NNP	O
twice	RB	FREQ
daily	RB	FREQ
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
into	IN	O
each	DT	O
eye	NN	O
using	VBG	O
a	DT	O
single	JJ	DOS
-	:	O
use	NN	O
container	NN	O
.	.	O

It	PRP	O
should	MD	O
not	RB	O
be	VB	O
less	JJR	O
than	IN	O
0.5	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
recommended	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
500	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
to	TO	O
2000	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
1000	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
or	CC	O
four	CD	DOS
500	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
bedtime	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
intravenous	JJ	O
infusion	NN	O
initially	RB	O
should	MD	O
be	VB	O
2	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
and	CC	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
is	VBZ	O
6.3	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMJEVITA	NNP	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
plaque	JJ	WHO
psoriasis	NN	WHO
(	(	O
Ps	NNP	O
)	)	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
80	CD	DOS
mg	NN	UNIT
,	,	O
followed	VBN	O
by	IN	O
40	CD	DOS
mg	NNS	UNIT
given	VBN	O
every	DT	FREQ
other	JJ	FREQ
week	NN	FREQ
starting	VBG	O
one	CD	PER
week	NN	PER
after	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
.	.	O

Rapidly	RB	O
make	VB	O
15	CD	O
jabs	NN	O
of	IN	O
the	DT	O
needle	JJ	O
perpendicular	NN	O
to	TO	O
the	DT	O
skin	NN	O
through	IN	O
the	DT	O
vaccine	NN	O
droplet	NN	O
to	TO	O
puncture	VB	O
the	DT	O
skin	NN	O
,	,	O
within	IN	O
a	DT	O
diameter	NN	O
of	IN	O
about	IN	O
5	CD	O
mm	NNS	O
.	.	O

Based	VBN	O
on	IN	O
cross	NN	O
-	:	O
study	NN	O
comparisons	NNS	O
,	,	O
the	DT	O
clearance	NN	O
of	IN	O
zafirlukast	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
(	(	WHO
65	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
)	)	WHO
,	,	O
such	JJ	O
that	IN	O
Cmax	NNP	O
and	CC	O
AUC	NNP	O
are	VBP	O
approximately	RB	O
twice	RB	O
those	DT	O
of	IN	O
younger	JJR	WHO
adults	NNS	WHO
.	.	O

Continuous	JJ	O
maintenance	NN	O
therapy	NN	O
with	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
instituted	VBN	O
when	WRB	O
the	DT	O
white	JJ	O
blood	NN	O
cell	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
4000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
100000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mcL	NN	O
.	.	O

Acute	NNP	O
epididymo	SYM	O
-	:	O
orchitis	NN	O
caused	VBN	O
by	IN	O
C.	NNP	O
trachomatis	NN	O
:	:	O
100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJ	PER
10	CD	PER
days	NNS	PER
.	.	O

Energy	NNP	O
requirements	NNS	O
for	IN	O
children	NNS	WHO
between	IN	WHO
1	CD	WHO
and	CC	WHO
7	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
are	VBP	O
approximately	RB	O
75	CD	O
to	TO	O
90	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
for	IN	O
children	NNS	WHO
7	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
60	CD	O
to	TO	O
75	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
;	:	O
and	CC	O
for	IN	O
ages	NNS	WHO
12	CD	WHO
to	TO	WHO
18	CD	WHO
years	NNS	WHO
,	,	O
30	CD	O
to	TO	O
60	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
a	DT	O
single	JJ	DOS
capsule	NN	UNIT
should	MD	O
not	RB	O
be	VB	O
divided	VBN	O
.	.	O

Administer	NNP	O
additional	JJ	O
boluses	NNS	O
as	IN	O
needed	VBN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
a	DT	O
total	JJ	O
dosage	NN	O
of	IN	O
50	CD	DOS
mg	NN	UNIT
.	.	O

Pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
administer	VB	O
this	DT	O
product	NN	O
under	IN	O
adult	JJ	WHO
supervision	NN	O
.	.	O

In	IN	O
some	DT	O
acute	JJ	O
cases	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
more	JJR	O
satisfactory	JJ	O
to	TO	O
administer	VB	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
500	CD	DOS
mg	NN	UNIT
followed	VBN	O
by	IN	O
125	CD	DOS
mg	NNS	UNIT
or	CC	O
250	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
case	NN	O
.	.	O

Patients	NNS	WHO
previously	RB	WHO
receiving	VBG	WHO
other	JJ	WHO
niacin	JJ	WHO
products	NNS	WHO
should	MD	O
be	VB	O
started	VBN	O
with	IN	O
the	DT	O
recommended	VBN	O
NIASPAN	NNP	O
titration	NN	O
schedule	NN	O
(	(	O
see	VB	O
Table	NNP	O
11	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
subsequently	RB	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
patient	JJ	O
response	NN	O
.	.	O

Figure	NN	O
1	CD	O
:	:	O
Examples	NNS	O
of	IN	O
Amyvid	NNP	O
negative	JJ	O
scans	NNS	O
(	(	O
top	JJ	O
two	CD	O
rows	NNS	O
)	)	O
and	CC	O
positive	JJ	O
scans	NNS	O
(	(	O
bottom	JJ	O
two	CD	O
rows	NNS	O
)	)	O
.	.	O

Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
for	IN	O
a	DT	O
full	JJ	O
16	CD	PER
weeks	NNS	PER
to	TO	O
a	DT	O
defined	VBN	O
treatment	NN	O
area	NN	O
on	IN	O
the	DT	O
face	NN	O
or	CC	O
scalp	NN	O
(	(	O
but	CC	O
not	RB	O
both	DT	O
concurrently	RB	O
)	)	O
.	.	O

Aldara	NNP	O
Cream	NNP	O
is	VBZ	O
packaged	VBN	O
in	IN	O
single	JJ	DOS
-	:	O
use	NN	O
packets	NNS	O
,	,	O
with	IN	O
12	CD	DOS
packets	NNS	UNIT
supplied	VBN	O
per	IN	O
box	NN	O
.	.	O

Second	JJ	O
Dose	NNP	O
:	:	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
diluted	VBD	O
in	IN	O
250	CD	DOS
mL	NN	UNIT
of	IN	O
diluent*	NN	O
administered	VBN	O
over	IN	O
4	CD	O
hrs	NNS	O

For	IN	O
convenience	NN	O
,	,	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
adequately	RB	WHO
treated	VBN	WHO
with	IN	O
20	CD	DOS
mg	NNS	UNIT
of	IN	O
quinapril	NN	O
and	CC	O
25	CD	DOS
mg	NN	UNIT
of	IN	O
hydrochlorothiazide	NN	O
and	CC	O
experience	NN	O
no	DT	O
significant	JJ	O
electrolyte	NN	O
disturbances	NNS	O
may	MD	O
instead	RB	O
wish	VB	O
to	TO	O
receive	VB	O
ACCURETIC	NNP	O
20	CD	O
/	NN	O
25	CD	O
.	.	O

Figures	NNS	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
provide	NN	O
examples	NNS	O
of	IN	O
negative	JJ	O
and	CC	O
positive	JJ	O
scans	NNS	O
.	.	O

Titration	NN	O
to	TO	O
doses	NNS	O
above	IN	O
90	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

